HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, with generic tenofovir disoproxil fumarate/emtricitabine ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

Now more than 40 years since the discovery of the HIV pandemic. 8 The results of this study provide reason for optimism that offering long-acting antiretroviral options for PrEP, as part of a flexible ...

Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the ...

Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.

Credit: elenavolf/Shutterstock. ViiV Healthcare has announced plans to triple its annual supply of long-acting cabotegravir for HIV pre-exposure prophylaxis (PrEP) to at least two million doses. These ...

The Centers for Disease Control and Prevention (CDC) has announced the five health departments that will receive federal funding to provide generic pre-exposure prophylaxis (PrEP) to prevent HIV as ...